Temazepam

Summary

Temazepam (CHEMBL967) is an approved small molecule (ATC N05CD07); indicated across 6 conditions including insomnia and chronic obstructive pulmonary disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05CD07
• Indications: 6 conditions
• Clinical trials: 6
• Chemistry: 300.74 Da · C16H13ClN2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL967
Name	Temazepam
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5391
ATC	N05CD07
Molecular formula	C16H13ClN2O2
Molecular weight	300.74
InChIKey	SEQDDYPDSLOBDC-UHFFFAOYSA-N

SMILES: CN1C2=C(C=C(C=C2)Cl)C(=NC(C1=O)O)C3=CC=CC=C3

IUPAC name: 7-chloro-3-hydroxy-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one

Also known as: (rs)-temazepam, Kentepam, Normison, NSC-246303, Restoril, Temaz, Temazepam, Temazepam civ, WY-3917, SID29215382, TEMAZEPAM, temazepam

Patent coverage: 8,496 distinct patent families (25,646 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 25,547 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Prelamin-A/C, Kappa-type opioid receptor, cGMP-inhibited 3’,5’-cyclic phosphodiesterase 3A, Gamma-aminobutyric acid receptor subunit alpha-1.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P62813	7.36	AC50	44	nM	CHEMBL_ACT_25130811
LMNA	6.55	Potency	281.8	nM	CHEMBL_ACT_3621546
PDE3A	5.52	AC50	3000	nM	CHEMBL_ACT_25190911
OPRK1	5.04	AC50	9191	nM	CHEMBL_ACT_25129630

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
insomnia	4	MONDO:0013600	EFO:0004698
chronic obstructive pulmonary disease	3	MONDO:0005002	EFO:0000341
anxiety	3	MONDO:0011918	EFO:0005230
dementia	3	MONDO:0001627	HP:0000726
depressive disorder	3	MONDO:0002050	MONDO:0002050

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE4	2
PHASE3	2
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00465972	PHASE4	COMPLETED	The Treatment of Insomnia in Patients With HIV Disease
NCT02153788	PHASE4	COMPLETED	Efficacy and Safety of Temazepam in HIV Seropositive Patients With Insomnia
NCT00245661	PHASE3	COMPLETED	Effects of Temazepam in Patients With Chronic Pulmonary Obstructive Disease
NCT02374567	PHASE3	TERMINATED	Pharmacovigilance in Gerontopsychiatric Patients
NCT00940550	PHASE1	COMPLETED	Study to Investigate the Effects of Melatonin, Temazepam & Zolpidem on Sleep EEG in Men and Women
NCT01519544	Not specified	COMPLETED	Comparison of Temazepam and Acetazolamide to Treat Difficulty Sleeping at High Altitude

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).